

GLOBAL X

by Mirae Asset

Global X Select ETFs

April 2025

China Global Leaders ETF (3050)

China Biotech ETF (2820)

China Consumer Brand ETF (2806)

FTSE Greater China ETF (3470)

Hang Seng TECH Components Covered Call Active ETF (3417)

G2 Tech ETF (3402)









Permanent Innovator

<https://www.globalxetfs.com.hk/>

Global X Selected ETFs



For Hong Kong Investors Only
Securities Mentioned Are for Market Commentary Illustration Only

Product Name	Investment Points	Top 10 Holding(%)
<div>China Global Leader ETF (3050)</div> <div></div>	Chinese companies, forged by fierce domestic competition, have evolved into leaders on the global stage. Their competitive advantage is derived not only from quality and cost efficiency but also from advancements in technology and innovation. China Global Leaders exemplifies the strength of China's high-tech industry and is well positioned to benefit from China market rally thanks to its diversified exposure to a broad range of high-tech areas, a methodology focused on large-cap sector leaders and its H+A share exposure.	<div><div>SMIC9.5</div><div>Alibaba9.2</div><div>Xiaomi8.9</div><div>BYD8.5</div><div>Tencent7.5</div><div>CATL6.2</div><div>Midea5.5</div><div>Trip.com4.4</div><div>Luxshare Precision3.2</div><div>ZTE2.9</div></div>
<div>China Biotech ETF (2820/9820)</div> <div></div>	On the back of low valuation and investor positioning, we see favourable risk-return profile for China biotech sector as bolstered by domestic policy support, improving corporate earnings, more favourable macro factors, and ongoing globalization themes. China's macro easing policy and US FOMC rate cuts bode well for better funding environment for biotech companies to support R&D activity. Profitability improvement and commercialization ramp-up for biotech companies could lead to improving investor sentiments towards China healthcare. AI application in biotech sectors could further accelerate with the emergence of cost-efficient models, which could bring further efficiency gains and cost savings for biotech companies.	<div><div>Wuxi Biologics9.9</div><div>Innovent Biologics8.9</div><div>WuXi AppTec8.8</div><div>Jiangsu Hengrui8.3</div><div>Akeso6.6</div><div>Sino Biopharmaceutical4.9</div><div>Shanghai RAAS Blood4.4</div><div>Zai Lab4.2</div><div>MGI Tech3.4</div><div>Hansoh Pharmaceutical3.0</div></div>
<div>China Consumer Brand ETF (2806/9806)</div> <div></div>	Consumer was reaffirmed as a policy focus during recent Two Sessions, followed by the announcement of the "Action Plan to Boost Consumption", which outlines 30 initiatives, including increasing salaries, enhancing spending power, improving product/service quality, and promoting trade-in/upgrade. As the macroeconomy improves, the property market stabilizes, and supportive policies are implemented, consumer sentiment is expected to strengthen.	<div><div>Li Auto10.1</div><div>Kweichow Moutai9.0</div><div>Wuliangye Yibin8.8</div><div>Midea8.3</div><div>Trip.com7.7</div><div>Yum China7.0</div><div>ANTA5.2</div><div>Haier4.2</div><div>H World4.2</div><div>Seres3.9</div></div>
<div>FTSE Greater China ETF (3470)</div> <div></div>	<p>3470 enables investors to invest in a basket of companies across greater China markets, encompassing a wide range of sectors, all at a lower cost with a total expense ratio of 0.15%.</p> <p>The HK and China markets are attracting global investors' attention on DeepSeek moment and policy tailwinds, while Taiwan market outlook remains positive under the global AI development with its world-leading semiconductor industries.</p>	<div><div>TSMC9.0</div><div>Tencent8.9</div><div>Alibaba6.7</div><div>HSBC4.8</div><div>Meituan2.7</div><div>Xiaomi2.6</div><div>AIA2.0</div><div>CCB1.9</div><div>MediaTek1.6</div><div>BYD1.5</div></div> <div>Source: Mirae Asset, 27 March 2025</div>
<div>Hang Seng TECH Components Covered Call Active ETF(3417)</div> <div></div>	We see upside potential for China Biotech Sector as bolstered by domestic policy support and Chinese companies' overseas expansion. China's macro easing policy and US FOMC rate cuts bode well for better funding environment for biotech companies to support R&D activity. Biotech sector valuation is nearing 5 year trough. Profitability improvement and commercialization ramp-up for biotech companies could lead to improving investor sentiments towards China healthcare. AI application in biotech sectors could further accelerate with the emergence of cost-efficient models, which could bring further efficiency gains and cost savings for biotech companies.	<div><div>Xiaomi6.8</div><div>Tencent6.5</div><div>JD.com6.5</div><div>Alibaba6.4</div><div>Meituan6.3</div><div>SMIC5.9</div><div>Kuaishou5.2</div><div>Li Auto4.4</div><div>Xpeng4.1</div><div>Netease3.4</div></div> <div>Source: Mirae Asset, 27 March 2025</div>
<div>G2 Tech ETF (3402)</div> <div></div>	The ETF invests in US and China technology leaders, offering a more balanced portfolio to capture the complementary strong suits of US and China technology. The recent development in China technology across AI, humanoid robot, and smart driving is regaining global investors' attention on the innovation capability of Chinese companies, and could drive a more sustainable rerating on Chinese technology stocks. For US, the substantial investments into AI continues and tech giants are poised to benefit from AI development and adoptions.	<div><div>SMIC11.0</div><div>Xiaomi9.0</div><div>BYD6.6</div><div>Apple6.2</div><div>Alibaba6.1</div><div>Tencent5.3</div><div>Kuaishou5.1</div><div>NVIDIA5.0</div><div>Microsoft4.9</div><div>Meituan4.3</div></div>

Source: Mirae Asset, 28 February 2025, unless otherwise stated.

Global X China Global Leader ETF (3050)

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

Global X China Global Leaders ETF's (the "Fund's") investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.

The Fund may invest in small and/or mid-sized companies. The stock of small-capitalisation and mid-capitalisation companies may have lower liquidity and their prices are more volatile to adverse economic developments than those of larger capitalisation companies in general. The Fund's investments are concentrated in companies which are either headquartered or incorporated in Mainland China, Hong Kong or Macau. The Fund's value may be more volatile than that of a fund with a more diverse portfolio.

China is an emerging market. The Fund invests in Chinese companies which may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.

The trading price of the Fund's unit (the "Unit") on the Stock Exchange of Hong Kong is driven by market factors such as demand and supply of the Unit. Therefore, the Units may trade at a substantial premium or discount to the Fund's net asset value.

The Fund's synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments ("FDIs"), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Sub-Fund.

As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from realisation requests. COM-2025.03.31-MKT-Select-Flyer



Permanent Innovator

<https://www.globalxetfs.com.hk/>

Global X China Global Leaders ETF (3050)



For Hong Kong
Investors Only

- Invest in Select large-cap companies based on industry leadership and global presence.
- Invest in a broader range of high-end industries that can deliver long-term growth, leveraging China’s deep manufacturing ecosystem and global competitiveness.
- All China Concept with H-shares and A-shares exposure

Key Information

Listing Date	2021.03.11
Ongoing Charges over a Year ¹	0.68%
Exchange	HKEX
Reference Index ²	FactSet China Global Leaders Index NTR

1. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. The ongoing charges figure is an annualised figure based on the ongoing expenses of the Fund, expressed as a percentage of the Fund's average net asset value over the same period. The figure may vary from year to year. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. The single management fee does not include the fees related to FDIs (including swaps) entered into by the Fund. The ongoing charges of the Fund are fixed at 0.68% of the Fund's net asset value, which is equal to the current rate of the management fee of the Fund. For the avoidance of doubt, any ongoing expenses of the Fund exceeding the ongoing charges of the Fund (i.e. the management fee) shall be borne by the Manager and shall not be charged to the Fund. Please refer to the Key Facts Statement and the Prospectus for further details. 2. The Underlying Index is a net total return, free float market capitalization weighted index. A net total return index reflects the reinvestment of dividends or coupon payments, after deduction of any withholding tax (including any surcharges for special levies, if applicable).


Top 10 Holdings

Company Name	Weighting (%)
SMIC	9.5
Alibaba	9.2
Xiaomi	8.9
BYD	8.5
Tencent	7.5
CATL	6.2
Midea	5.5
Trip.com	4.4
Luxshare	3.2
ZTE	2.9

Source: Mirae Asset, 28 February 2025


Index Methodology

China Global Leaders Index Selection Process



Source: Solative, May 2024


Sector Breakdown



Source: Mirae Asset, 31 March 2025. Note: Securities are categorized according to Mirae Asset research for illustrative purposes.

All China Concept with H-shares and A-shares exposure

Listed Exchange Breakdown (%)



Source: Mirae Asset, 31 March 2025.


Emergence of Chinese Global Champions: BYD Ranked No.1 in Global EV Sales in 2024

Accumulative Global EV Deliveries (BEV+PHEV, incl. Commercial)						
Rank	Auto Group	Units (K)			Market Share	
		2023	2024	YoY	2023	2024
1	BYD	2,885	4,137	43.4%	20.6%	23.5%
2	Tesla	1,809	1,789	-1.1%	12.9%	10.1%
3	Geely	867	1,386	59.8%	6.2%	7.9%
4	SAIC	907	1,018	12.2%	6.5%	5.8%
5	Volkswagen	996	999	0.3%	7.1%	5.7%
6	Changan	471	694	47.4%	3.4%	3.9%
7	Hyundai & Kia	560	550	-1.8%	4.0%	3.1%
8	BMW Group	527	534	1.2%	3.8%	3.0%
9	Chery	155	520	236.0%	1.1%	2.9%
10	Li Auto	381	501	31.5%	2.7%	2.8%
Others		4,427	5,505	24.4%	31.7%	31.2%
Total		13,984	17,633	26.1%	100.0%	100.0%

Source: SNE Research, January 2025


Emergence of Chinese Global Champions: China Brands' Global Smartphone Share

Global Smartphone Market Share



Source: Counterpoint, December 2024


High Quality Constituents with Attractive Valuation



Source: Bloomberg, Mirae Asset, 1 April 2025. Note: data in the chart are calculated based on holdings of China Global Leaders (3050 HK) and Hang Seng Tech (2837 HK) as of 31 March 2025.

Emergence of Chinese Global Champions: CATL, the World's Largest Battery Maker


Market Share of World's Top EV Battery Makers (2024)



Source: SNE Research, CnEVPost, February 2025

China's Manufacturing Prowess

Net Export of Manufactured Goods



Source: CSIS, World Trade Organization, 2025

Global X China Biotech ETF (2820/9820)

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

Global X China Biotech ETF's (the "Fund's") investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.


Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly.

China is an emerging market. The Fund invests in Chinese companies which may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.

The trading price of the Fund's unit (the "Unit") on the Stock Exchange of Hong Kong is driven by market factors such as demand and supply of the Unit. Therefore, the Units may trade at a substantial premium or discount to the Fund's net asset value.

The Fund's synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments ("FDIs"), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Sub-Fund.

As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from realisation requests. COM-2025.04.02-MKT-Select-Flyer-CBIO



Permanent Innovator

<https://www.globalxetfs.com.hk/>

Global X China Biotech ETF (2820/9820)



For Hong Kong
Investors Only

- We see upside potential for China Biotech Sector as bolstered by domestic policy support and Chinese companies’ overseas expansion. China’s macro easing policy and US FOMC rate cuts bode well for better funding environment for biotech companies to support R&D activity.
- Biotech sector valuation is nearing 5 year trough. Profitability improvement and commercialization ramp-up for biotech companies could lead to improving investor sentiments towards China healthcare.
- AI application in biotech sectors could further accelerate with the emergence of cost-efficient models, which could bring further efficiency gains and cost savings for biotech companies.

Key Information

Listing Date	2019.07.25
Ongoing Charges over a Year ¹	0.68%
Exchange	HKEX
Reference Index ²	Solactive China Biotech Index NTR


Source: Mirae Asset, February 2025 1. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. The ongoing charges figure is an annualized figure based on the ongoing expenses of the Fund, expressed as a percentage of the Fund’s average Net Asset Value of the Listed Class of Units of the Fund over the same period. The figure may vary from year to year. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. The single management fee does not include fees related to the FDIs (including swaps) entered into by the Fund. The ongoing charges of the Fund are fixed at 0.68% of the Fund’s Net Asset Value of the Listed Class of Units of the Fund, which is equal to the current rate of the management fee of the Listed Class of Units of the Fund. For the avoidance of doubt, any ongoing expenses of the Fund exceeding the ongoing charges of the Fund (i.e. the management fee) shall be borne by the Manager and shall not be charged to the Fund. Please refer to the Product Key Facts and the Prospectus for further details. The Underlying Index is a net total return, free float market capitalization weighted index. A net total return index reflects the reinvestment of dividends or coupon payments, after deduction of any withholding tax (including any surcharges for special levies, if applicable).

Top 10 Holdings

Company Name	Weighting (%)
Wuxi Biologics	9.9
Innovent Biologics	8.9
WuXi AppTec	8.8
Jiangsu Hengrui	8.3
Akeso	6.6
Sino Biopharmaceutical	4.9
Shanghai RAAS Blood	4.4
Zai Lab	4.2
MGI Tech	3.4
Hansoh Pharmaceutical	3.0


Source: Mirae Asset, 28 February 2025

China Healthcare Stock’s Market Cap Contribution Still Lags Behind Peers




Source: JP Morgan, January 2025

Going Global – License-Out Deals Saw Increase in Both Case Numbers and Value




Source: JP Morgan, January 2025

Going Global - Innovative Drugs Launched Overseas Show A Good Sales Ramp-up Trend




Source: UBS, January 2025

Government's Basic Medical Insurance (BMI) Fund Remains Balanced in 2024




Source: JP Morgan, January 2025

Innovative Drug Sales Remain Robust In China, With 2024 Poised To Surpass 2023




Source: JP Morgan, January 2025

China Accounts for Increasing Shares of Global Drug Development




Source: Citeline, LEK, February 2025

Valuation – China Biotech Stocks Trades at a Substantial Discount



Source: Goldman Sachs, February 2025

Sector Breakdown



Source: Mirae Asset, February 2025

Global X China Consumer Brand ETF (2806/9806)

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

Global X China Consumer Brand ETF's (the "Fund's") investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.

The performance of companies in the consumer sector are correlated to the growth rate of the global market, individual income levels and their impact on levels of domestic consumer spending in the global markets, which in turn depend on the worldwide economic conditions, which have recently deteriorated significantly in many countries and regions and may remain depressed for the foreseeable future.

China is an emerging market. The Fund invests in Chinese companies which may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.

The trading price of the Fund's unit (the "Unit") on the Stock Exchange of Hong Kong is driven by market factors such as demand and supply of the Unit. Therefore, the Units may trade at a substantial premium or discount to the Fund's net asset value.

The Fund's synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments ("FDIs"), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Sub-Fund.

As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from realisation requests. COM-2025.03.31-MKT-Select-Flyer



Permanent Innovator

<https://www.globalxetfs.com.hk/>

Global X China Consumer Brand ETF (2806/9806)



For Hong Kong
Investors Only

- Policy stimulus remains key to enhancing consumer sentiment and boosting stock performance for China consumer in 2025.
- Macroeconomic recovery, bolstered by supportive policies and stabilization of property market, presents the largest upside potential for China’s consumer sector in 2025, especially given that demand was under pressure across nearly all subsectors in 2024.
- By subsector, sectors directly targeted by stimulus initiatives, such as home appliance and auto under extended consumer goods trade-in programs, as well as sectors sensitive to macroeconomic changes, such as Baijiu, stand to better benefit.

Key Information

Listing Date	2020.01.17
Ongoing Charges over a Year ¹	0.68%
Exchange	HKEX
Reference Index ²	Solactive China Consumer Brand Index NTR


1. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. For the first 12-month period from the launch of the Fund, the ongoing charges of the Listed Class of Units are capped at 0.68% of the average NAV of the relevant class. Any ongoing expenses exceeding 0.68% of the average NAV of the relevant class will be borne by the Manager and will not be charged to the Fund. Please refer to the Key Facts Statement for the section headed “Ongoing fees payable by the Fund” below and the Prospectus for further details. 2. The Underlying Index is a net total return, equally weighted index. A net total return index reflects the reinvestment of dividends or coupon payments, after deduction of any withholding tax (including any surcharges for special levies, if applicable). 3. Dividend is not guaranteed, distributions may be made out of capital or income at the Manager’s discretion. Positive distribution does not imply positive return. Please refer to the IMPORTANT INFORMATION section above and the Fund’s prospectus for further details.

Top 10 Holdings

Company Name	Weighting (%)
Li Auto	10.1
Kweichow Moutai	9.0
Wuliangye Yibin	8.8
Midea	8.3
Trip.com	7.7
Yum China	7.0
ANTA	5.2
Haier	4.2
H World	4.2
Seres Group	3.9

Source: Mirae Asset, 28 February 2025

Industry Breakdown



Source: Mirae Asset, 28 February 2025

China Retail Sales Saw Sequential Improvements




Source: Bloomberg, February 2025

Consumer at the Center of Government Policy Focus

Date	Relevant Authorities	Content
Jul-24	Central Govt.	Consumer goods trade-in program: Rmb300bn long-term special treasury bond quota this year to support consumer goods trade-in and equipment upgrade programs.
Jul-24	Politburo Meeting	Guidance on consumption: Underscored the importance of stimulating consumption and highlighted enhancing service consumption
Sep-24	Shanghai DRC	Consumption vouchers: Rmb500mn vouchers for dining, accommodation, movie tickets and sports .
Sep-24	Central Govt.	Cash subsidies for low income groups: one-off cash handouts to people living in extreme poverty.
Sep-24	Politburo Meeting	Guidance on consumption: Combine social welfare and consumption mix upgrade. Cultivate new consumption formats and facilitate stable pricing of food and utilities.
Dec-24	Guangzhou Govt.	Consumption vouchers: Guangzhou launched 1st round of Rmb100m dining vouchers
Dec-24	CEWC	Guidance on consumption: boosting domestic demand as the top economic work for 2025, up from the second place for 2024.
Jan-25	NDRC	Consumer trade-in: Purchase of smartphones, tablets, smartwatches will be included in the trade-in scheme
Mar-25	NPC	Consumer trade-in: the size of trade-in subsidies for consumer goods is doubled to Rmb300bn
Mar-25	State Council	Consumption Stimulus Action Plan: 30 actions covering eight areas incl: 1) boost income; 2) enhance social welfare; 3) stimulate service consumption; 4) expand trade-in policy and stabilize the housing market; 5) support new consumption; 6) facilitate consumption via paid leave scheme etc; 7) ease unnecessary restrictions; 8) consummate supporting policies in fiscal, investment, consumer credit, etc.


Source: Public information, Morgan Stanley, Mirae Asset, March 2025

China Consumer Valuation Remain Attractive




Source: Factset, Morgan Stanley, March 2025

Signs of Stabilization in Property Market




Source: Centaline; BofA Global Research, March 2025

Tourism: Robust Recovery



Source: Ministry of Culture and Tourism, Goldman Sachs, February 2025

Home Appliance: AC Shipments Maintained Strong Momentum under 'Trade-in' Subsidies



Source: ChinaIOL, UBS, February 2025. Note: Production planning data from Feb 2025.

Global X FTSE Greater China ETF (3470)

Investors should not base investment decisions on this content alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

Global X FTSE Greater China ETF (the "Fund")'s investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the FTSE MPF Greater China Index (the "Index").

The Fund is subject to concentration risk as a result of tracking the performance of a single geographical region or country (Greater China). The Fund may likely be more volatile than a broad-based fund, such as a global equity fund, as it is more susceptible to fluctuations in value of the Index resulting from adverse conditions in the region.

The Fund invests in certain emerging markets such as Mainland China and Taiwan. This may involve increased risks and special considerations not typically associated with investment in more developed markets, such as liquidity risks, currency risks/control, political and economic uncertainties, legal and taxation risks, settlement risks, custody risk and the likelihood of a high degree of volatility.

Listed companies on the ChiNext market and/or STAR Board are usually of emerging nature with smaller operating scale. In particular, listed companies on ChiNext market and/or STAR Board are subject to higher fluctuation in stock prices and liquidity risks, Over-valuation risk, Differences in regulation, Delisting risk, and Concentration risk.

The Fund may invest in mid-capitalisation companies, which may have lower liquidity and their prices are more volatile to adverse economic developments than those of larger capitalisation companies in general.

The borrower may fail to return the securities in a timely manner or at all. The Fund may as a result suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from redemption requests. As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund.

There are risks and uncertainties associated with the current Mainland China tax laws, regulations and practice in respect of capital gains realized via Stock Connect on the Fund's investments in Mainland China (which may have retrospective effect). Any increased tax liabilities on the Fund may adversely affect the Fund's value.

The trading price of the Shares on the SEHK is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Fund's Net Asset Value.

Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment. COM-2025.03.31-MKT-Select-Flyer

Permanent Innovator

<https://www.globalxetfs.com.hk/>



Global X FTSE Greater China ETF (3470)



For Hong Kong
Investors Only

- 3470 enables investors to invest in a basket of companies across greater China markets, encompassing a wide range of sectors, all at a lower cost with a total expense ratio of 0.15%¹.
- HK/China: DeepSeek has prompted global investors to reevaluate the China market. With improving macroeconomic conditions and supportive policy roll-out, we see upside potential from broader HK and China markets.
- Taiwan: with world-leading semiconductor industries, Taiwan market outlook remains positive under the global AI development.

Source: Mirae Asset, March 2025. 1. As the Fund is newly set up, this figure is an estimate only and represents the sum of the estimated ongoing charges over a 12-month period, expressed as a percentage of the estimated average NAV of the Listed Class of Shares over the same period. It may be different upon actual operation of the Fund and may vary from year to year. As the Fund adopts a single management fee structure, the estimated ongoing charges of the Fund will be equal to the amount of the single management fee, which is capped at 0.15% of the average NAV of the Listed Class of Shares of the Fund. Any ongoing expenses exceeding 0.15% of the average NAV of the Listed Class of Shares of the Fund will be borne by the Manager and will not be charged to the Fund. Please refer to Product Key Facts and the Prospectus for details.

Key Information

Listing Date	2025.03.28
Ongoing Charges over a Year ¹	0.15%
Exchange	HKEX
Reference Index	FTSE MPF Greater China Index


Source: Mirae Asset, March 2025. 1. As the Fund is newly set up, this figure is an estimate only and represents the sum of the estimated ongoing charges over a 12-month period, expressed as a percentage of the estimated average NAV of the Listed Class of Shares over the same period. It may be different upon actual operation of the Fund and may vary from year to year. As the Fund adopts a single management fee structure, the estimated ongoing charges of the Fund will be equal to the amount of the single management fee, which is capped at 0.15% of the average NAV of the Listed Class of Shares of the Fund. Any ongoing expenses exceeding 0.15% of the average NAV of the Listed Class of Shares of the Fund will be borne by the Manager and will not be charged to the Fund. Please refer to Product Key Facts and the Prospectus for details.

Index Top 10 Holdings

Company Name	Weighting (%)
Tencent	9.1
TSMC	8.8
Alibaba	6.6
HSBC	5.0
Meituan	2.7
Xiaomi	2.6
AIA	2.0
China Construction Bank	1.9
MediaTek	1.6
Hon Hai Precision	1.5


Source: FTSE Russell, 28 February 2025

Index Market Breakdown




Source: FTSE Russell, 28 February 2025

Index Sector Breakdown




Source: FTSE Russell, 28 February 2025

China Market Emerges as Top Performer Since 2024



Source: Bloomberg, data as of 28 February 2025. Indexed to 100 on 1 January 2024

China Market Still Trades at a Discount Despite Recent Rally



Source: Bloomberg, data as of 24 March 2025

China Economy to Bottom Out in 2025: Property Market Showed Stabilization




Source: Wind, Citi, March 2025

Policymaker Demonstrated Pro-growth Stance with Focus on Tech and Consumption

- A new tech board for the bond market**
To facilitate direct debt financing by tech companies and PEs
- A state startup fund**
The fund could reach Rmb1trn in size after incorporating private investment
- Expanded quota on PBoC sci-tech relending facility**
From Rmb500bn to Rmb0.8-1trn
- Rise in on-budget tech spending**
Reaching Rmb1.2trn, or 8.3%Y (vs. 4.4%Y for overall fiscal spending)


Source: NPC, Morgan Stanley, March 2025

Chinese Companies are Ramping Up Shareholder Returns



Source: UBS, Wind, January 2025

Taiwan: Ride on AI Development



Source: Company data, Morgan Stanley, January 2025

Global X Hang Seng TECH Components Covered Call Active ETF (3417)

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including product features and the risk factors. Investment involves risks. Past performance is not indicative of future performance. There is no guarantee of the repayment of the principal. Investors should note:

Global X Hang Seng TECH Components Covered Call Active ETF (the "Fund") aims to generate income by primarily (i) investing in constituent equity securities in the Hang Seng TECH Index (the "Reference Index" or the "HS TECH"); and (ii) selling (i.e. "writing") call options on the Reference Index to receive payments of money from the purchaser of call options (i.e. "premium").

The objective of adopting a covered call strategy is to generate income and reduce potential loss against the downward market. Each time the Fund writes a HS TECH Call Option, the Fund receives a premium. If the value of the securities relating to the Reference Index held by the Fund declines, the premium that the Fund received for writing the HS TECH Call Option may reduce such loss to some extent. However, the downside of adopting a covered call strategy is that the Fund's opportunity to profit from an increase in the level of the Reference Index is limited to the strike price of the HS TECH Call Options written, plus the premium received.

The Fund employs an actively managed investment strategy. In addition to seeking to obtain exposure to the constituent equity securities in the Reference Index in substantially the same weightings as these securities have in the Reference Index through investing directly in constituent equity securities of the Reference Index and HS TECH ETF and long positions of HS TECH Futures, the Fund also writes call options on the Reference Index. For the avoidance of doubt, the Fund does not seek to track the Reference Index. The Fund may fail to meet its objective as a result of the implementation of investment process which may cause the Fund to underperform as compared to direct investments in the constituent equity securities of the Reference Index.

The market value of a HS TECH Call Option may be affected by an array of factors including but not limited to supply and demand, interest rates, the current market price of the Reference Index in relation to the strike price of the HS TECH Call Options, the actual or perceived volatility of the Reference Index and the time remaining until the expiration date. The Fund's ability to utilise HS TECH Call Options successfully will depend on the ability of the Manager to correctly predict future price fluctuations, which cannot be assured and are subject to market behaviour or unexpected events.

If a HS TECH Call Option expires and if there is a decline in the market value of the Reference Index during the option period, the premiums received by the Fund from writing the HS TECH Call Options may not be sufficient to offset the loss realised.

The Fund may write HS TECH Call Options over an exchange or in the OTC market. The HS TECH Call Options in the OTC markets may not be as liquid as exchange-listed options. There may be a limited number of counterparties which are willing to enter into HS TECH Call Options as purchasers or the Fund may find the terms of such counterparties to be less favorable than the terms available for listed options. Moreover, the SEHK may suspend the trading of options in volatile markets. If trading is suspended, the Fund may not be able to write HS TECH Call Options at times that may be desirable or advantageous to do so.

The use of futures contracts involves risks that are potentially greater than the risks of investing directly in securities and other more traditional assets. The risks include but not limited to market risk, volatility risk, leverage risk and negative roll yields and "contango" risk.

Investing in HS TECH Futures and writing HS TECH Call Options generally involve the posting of margin. Additional funds may need to be posted as margin to meet margin calls based upon daily marking to market of the HS TECH Futures and the HS TECH Call Options. Increases in the amount of margin or similar payments may result in the need for the Fund to liquidate its investments at unfavourable prices in order to meet margin calls. If the Fund is unable to meet its investment objective as a result of margin requirements imposed by the HKFE, the SEHK and/or the Fund's brokers, the Fund may experience significant losses.

HS TECH Futures and HS TECH Call Options are registered, cleared and guaranteed by the HKFE Clearing Corporation. In the event of the bankruptcy of the clearing house, the Fund could be exposed to a risk of loss with respect to its assets that are posted as margin.

The Fund is subject to concentration risk as a result of tracking the performance of securities incorporated in, or with the majority of revenue derived from, or with a principal place of business in, the Greater China region. The Fund may likely be more volatile than a broad-based fund, such as a global equity fund, as it is more susceptible to fluctuations resulting from adverse conditions in a single region. In addition, to the extent that the constituent securities of the Reference Index are concentrated in Hong Kong listed securities of a particular sector or market (i.e., technology), the investments of the Fund may be similarly concentrated. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments. The value of the Fund may be more susceptible to adverse conditions in such particular market/sector.

The borrower may fail to return the securities in a timely manner or at all. The Fund may as a result suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from redemption requests. As part of the securities lending transactions, the Fund must receive cash collateral of at least 100% of the valuation of the securities lent valued on a daily basis. However, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund.

The base currency of the Fund is HKD but the class currencies of the Shares are in HKD, RMB and USD. The Net Asset Value of the Fund and its performance may be affected unfavourably by fluctuations in the exchange rates between these currencies and the base currency and by changes in exchange rate controls.

Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment.

The trading price of the Shares on the SEHK is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Fund's Net Asset Value. COM-2025.03.31-MKT-Select-Flyer

Permanent Innovator

<https://www.globalxetfs.com.hk/>

Global X Covered Call Strategy




For Hong Kong
Investors Only

- **[Option Premium]** Covered Call Strategy based on Hang Seng Tech index may offers higher option premium income as compared to that of other major indices due to higher volatility
- **[Dividend]** ETF targets monthly distribution with option premium collected through monthly call option writing (Dividend rate is not guaranteed, distributions may be made out of capital)*




What is the Covered Call Strategy?

Covered Call Strategy Payoff



- ### Covered Call Features
- Generates potential income versus the underlying security itself due to the premiums received from selling call options.
 - Upside potential is capped in the event that the stock appreciates beyond the strike price.
 - Option premiums tend to increase during volatile markets, offering a potential risk management component.
 - No additional downside protection beyond the premiums received.

[Case study] Covered Call Index Performance In Specific Time



1. Source: Hang Seng Indexes; Annualised Income yield has been over 10% for HSI Covered Call Index, HSCI Covered Call Index since index inception in 24 Jun 2019, and HS Tech Index since 2021. Index yield is not equivalent to yield/return of the fund. Positive yield does not mean positive return. Covered call writing can limit the upside potential of the underlying security. Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment. Data as of 2024. The downside of adopting a covered call strategy is that the Fund's opportunity to profit from an increase in the level of the Reference Index is limited to the strike price of the relevant index's call options written, plus the premium received. If a call option expires and if there is a decline in the market value of the reference index during the option period, the premiums received by the Fund from writing the call option may not be sufficient to offset the loss realized.

Hang Seng TECH Components Covered Call Active ETF (3417)


For Hong Kong Investors Only


Key Information

Listing Date	2025.3.13	Reference Index	Hang Seng TECH Index
Ongoing Charges over a Year ²	0.75%	Distribution	Aim for Monthly Distributions (Dividend rate is not guaranteed, distributions may be made out of capital ¹)
Exchange	HKEX		
Minimum Investment	~5000 HKD		

Source: Mirae Asset Global Investments, March 2025


2. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. For the first 12-month period from the launch of the Fund, the ongoing charges of the Listed Class of Units are capped at 0.75% of the average NAV of the relevant class. Any ongoing expenses exceeding 0.75% of the average NAV of the relevant class will be borne by the Manager and will not be charged to the Fund. Please refer to the Key Facts Statement for the section headed "Ongoing fees payable by the Fund" below and the Prospectus for further details. Positive distribution does not mean positive return. Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment. The downside of adopting a covered call strategy is that the Fund's opportunity to profit from an increase in the level of the Reference Index is limited to the strike price of the relevant index's call options written, plus the premium received. If a call option expires and if there is a decline in the market value of the reference Index during the option period, the premiums received by the Fund from writing the call option may not be sufficient to offset the loss realized.

Hang Seng Tech Index – Option Premium Yield vs Implied Volatility



Source: Hang Seng Indexes; Bloomberg; Data as of February 2025. Note: Comparison of HS Tech . For illustration only

Option Premium Yield Comparison



Source: Hang Seng Indexes; Bloomberg; Data as of 31 December 2024. Note: Option premium data for Hang Seng Tech Index, HSCEI, and Hang Seng Index are from Hang Seng; Others are estimated using Bloomberg data. For reference only.

Global X G2 Tech ETF (3402)

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including product features and the risk factors. Investment involves risks. Past performance is not indicative of future performance. There is no guarantee of the repayment of the principal. Investors should note:

- Global X G2 Tech ETF (the "Fund")'s investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Mirae Asset G2 Tech Index (the "Index").
- The Fund will primarily use a full replication strategy through investing directly in constituent stocks of the Index in substantially the same weightings in which they are included in the Index (the "Replication Strategy").
- Where the adoption of the Replication Strategy is not efficient or practicable or where the Manager considers appropriate in its absolute discretion, the Manager may pursue a representative sampling strategy and hold a representative sample of the constituent securities of the Index selected by the Manager using rule-based quantitative analytical models to derive a portfolio sample (the "Representative Sampling Strategy").
- The Index is a new index. The Index has minimal operating history by which investors can evaluate its previous performance. There can be no assurance as to the performance of the Index. The Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history.
- Due to the concentration of the Index in the technology sector, the performance of the Index may be more volatile when compared to other broad-based stock indices. The price volatility of the Fund may be greater than the price volatility of exchange traded funds tracking more broad-based indices.
- The Fund has high exposure to technology themes. The technology business is subject to complex laws and regulations including privacy, data protection, content regulation, intellectual property, competition, protection of minors, consumer protection and taxation. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to the business practices, monetary penalties, increased cost of operations or declines in user growth, user engagement or advertisement engagement, or otherwise harm the technology business. All these may have impact on the business and/or profitability of the technology companies that may be invested by the Fund and this may in turn affect the Net Asset Value of the Fund.
- The base currency of the Fund is USD but the trading currencies of the Fund are in HKD and USD. The Net Asset Value of the Fund and its performance may be affected unfavourably by fluctuations in the exchange rates between these currencies and the base currency and by changes in exchange rate controls.
- The borrower may fail to return the securities in a timely manner or at all. The Fund may as a result suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from redemption requests. As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund.
- The trading price of the Shares on the SEHK is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Fund's Net Asset Value.
- Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment. COM-2025.03.31-MKT-Select-Flyer

Permanent Innovator

<https://www.globalxetfs.com.hk/>



Global X G2 Tech ETF (3402)



For Hong Kong
Investors Only

- Invest in leading technology companies in the two most influential countries – US and China. A more balanced portfolio capturing the complementary strong suits of global technology.
- “US Tech – AI is one of the most important technology of our time. It is still early days in AI development, we see significant room to grow in the AI industry.
- China Tech – Robust digital ecosystem offers ample monetization opportunities for internet giants. World leading EV supply chain fosters globally competitive EV and battery brands.

Key Information

Listing Date	2025.01.10
Ongoing Charges over a Year ¹	0.68%
Exchange	HKEX
Reference Index ²	Mirae Asset G2 Tech Index

1. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. The ongoing charges figure is an annualised figure based on the ongoing expenses of the Fund, expressed as a percentage of the Fund's average net asset value over the same period. The figure may vary from year to year. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. The single management fee does not include the fees related to FDIs (including swaps) entered into by the Fund. The ongoing charges of the Fund are fixed at 0.68% of the Fund's net asset value, which is equal to the current rate of the management fee of the Fund. For the avoidance of doubt, any ongoing expenses of the Fund exceeding the ongoing charges of the Fund (i.e. the management fee) shall be borne by the Manager and shall not be charged to the Fund. Please refer to the Key Facts Statement and the Prospectus for further details. 2. The Underlying Index is a net total return, free float market capitalization weighted index. A net total return index reflects the reinvestment of dividends or coupon payments, after deduction of any withholding tax (including any surcharges for special levies, if applicable).


Top 10 Holdings

Company Name	Weighting (%)
SMIC	11.0
Xiaomi	9.0
BYD	6.6
Apple	6.2
Alibaba	6.1
Tencent	5.3
Kuaishou	5.1
NVIDIA	5.0
Microsoft	4.9
Meituan	4.3

Source: Mirae Asset. Data as of 28 February 2025

US and China Leads R&D Investments

Gross domestic expenditures on R&D, \$bn




Spending adjusted for purchasing power parity

— United States — China — Japan — Germany
— South Korea — United Kingdom — France — Taiwan


Source: State of U.S. Science & Engineering Report, 2024

China and US Capture Global Technology Talents




Source: ASPI, 2023

Us and China Rank Top in Terms of High-Impact Publications in Almost All Critical Technology Areas




Source: ASPI, 2024

G2Tech Comprises of High Quality Companies




Source: Bloomberg, Data as of 6 Jan 2025

While Valuation is Significantly Lower than US Tech Indexes




Source: Bloomberg, Data as of 6 Jan 2025

Compelling Risk-adjusted Returns



Source: Bloomberg, Data as of 6 January 2025

Low Correlation Between US-China Tech Offers Better Diversification



Source: Factset, January 2025

Fund Map

Global X ETFs Hong Kong



A lineup that spans emerging trends and disruptive tech, income, core and commodities ETFs. Or simply put, we strive to offer investors something beyond ordinary.

This document is intended for Hong Kong Investors only.
The following list consists of ETFs traded on the HKD counter (excluding USD and RMB counters). March 2025.

Investing in the Equity ETF(s) may expose to risks (if applicable) including general investment risk, equity market risk, sector/market concentration risk, active / passive investment management risk, tracking error risk, trading risk, risk in investing financial derivative instruments, securities lending risk, distributions paid out of capital or effectively out of capital risk.
Investing in the S&P Crude Oil Futures Enhanced ER ETF may expose to risks (if applicable) including passive investment risk, crude oil market risk, futures contracts risk, risk of material non-correlation with spot/current market price of the West Texas Intermediate crude oil risk, margin risk, trading risk, risk of investing in fixed income securities, tracking error risk, termination risk.
Investing in the USD Money Market Active ETF may expose to risks including general investment risk, active investment management risk, interest rate risk, risks associated with bank deposits, concentration risk, currency risk, trading risk, credit rating risk, downgrading risk, counterparty risk and distributions paid out of capital or effectively out of capital risk.
Investing in the Fixed Income Passive ETF(s) may expose to risks (if applicable) including general investment risk, passive investment management risk, interest rate risk, emerging markets risk, risks associated with PRC inter-bank bond market, Foreign Access Regime and Bond Connect, concentration risk, RMB/USD currency risk, securities lending risk, trading risk, credit rating risk, downgrading risk, counterparty risk, tracking error risk and distributions paid out of capital or effectively out of capital risk.
Investing in the Covered Call Active ETF may expose to risks (if applicable) including active investment management risk, futures contracts risk, margin requirement risk, failure of clearing house risk, concentration risk, securities lending transaction risks, currency risk, distributions paid out of capital or effectively out of capital risk, and trading risks.

THEMATIC GROWTH

INCOME

CHINA

DISRUPTIVE TECHNOLOGY

- 2845 Global X China Electric Vehicle and Battery ETF
- 3191 Global X China Semiconductor ETF
- 2826 Global X China Cloud Computing ETF
- 2807 Global X China Robotics and AI ETF

PEOPLE & DEMOGRAPHICS

- 2820 Global X China Biotech ETF
- 2841 Global X China MedTech ETF
- 2806 Global X China Consumer Brand ETF

PHYSICAL ENVIRONMENT

- 2809 Global X China Clean Energy ETF

MULTI-THEME

- 3050 Global X China Global Leaders ETF
- 2815 Global X China Little Giant ETF

GLOBAL

DISRUPTIVE TECHNOLOGY

- 3185 Global X FinTech ETF
- 3139 Global X Electric Vehicle and Battery Active ETF
- 3006 Global X AI & Innovative Technology Active ETF
- 3422 Global X Innovative Bluechip Top 10 ETF
- 3402 Global X G2 Tech ETF
- 3401 Global X AI Infrastructure ETF

ASIA

DISRUPTIVE TECHNOLOGY

- 3119 Global X Asia Semiconductor ETF

MULTI-THEME

- 3150 Global X Japan Global Leaders ETF
- 3184 Global X India Select Top 10 ETF
- 3158 Global X K-pop and Culture ETF
- 3084 Global X India Sector Leader Active ETF
- 3104 Global X Emerging Markets Asia Active ETF



COMMODITIES

COMMODITIES

- 3097 Global X S&P Crude Oil Futures Enhanced ER ETF



CORE

CORE

- 3040 Global X MSCI China ETF
- 2837 Global X Hang Seng TECH ETF
- 3029 Global X Hang Seng ESG ETF
- 3470 Global X FTSE Greater China ETF

DIVIDEND

- 3110 Global X Hang Seng High Dividend Yield ETF
- 3116 Global X Asia Pacific High Dividend Yield ETF
- 3419 Global X HSI Components Covered Call Active ETF
- 3416 Global X HSCEI Components Covered Call Active ETF
- 3417 Global X Hang Seng TECH Components Covered Call Active ETF

Dividend is not guaranteed and may be paid out of capital

FIXED INCOME

- 3059 Global X Bloomberg MSCI Asia Ex Japan Green Bond ETF
- 3041 Global X FTSE China Policy Bank Bond ETF
- 3137 Global X USD Money Market ETF
- 3075 Global X Asia USD Investment Grade Bond ETF
- 3450 Global X US Treasury 3-5 Year ETF
- 3440 Global X US Treasury 0-3 Month ETF

Disclaimer

This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service. The views and information discussed or referred in this document are Data as of the date of publication. Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements. Investment involves risk. Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the funds will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the funds and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment. Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (Hong Kong) Limited ("MAGIHK") are reliable, but we make no representation as to their accuracy or completeness. Reliance upon information in this material is at the sole discretion of the investor. Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGIHK as stipulated by local laws and regulations. This document is not directed to any person in any jurisdiction where availability of this document is prohibited. Persons in respect of whom such prohibitions apply or persons other than those specified above must not access this document. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction. This document is issued by MAGIHK (Licensed by the Securities and Futures Commission for Types 1, 4 and 9 regulated activities under the Securities and Futures Ordinance). This document has not been reviewed by the Securities and Futures Commission or the applicable regulator in the jurisdiction and no part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGIHK. Copyright © 2025 Mirae Asset Global Investments. All rights reserved. COM-2025.03.27-MKT-fundmap-3470

Authors: HUANG Yimin and LIU Zijun (Licensed by the Securities and Futures Commission for Types 1 and 4 regulated activities under the Securities and Futures Ordinance). The authors and their associate(s) do not hold the securities/funds mentioned in the article. COM-2025.04.02-MKT-SelectFlyer-CBIO



GLOBAL X

by Mirae Asset

Permanent Innovator